We are rapidly translating the most cutting edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
Immunogenesis is focused on developing a pipeline of drugs that, in combination, will synergize to address the critical ingredients for effective immunity against "cold" tumors. 1) Generation of sufficient anti-tumor T cells; 2) protection and expansion of those cells in the tumor; and 3) reduction in hostile tumor metabolism.
We plan our clinical studies to treat patient populations most likely to experience optimal benefit. Further, we leverage novel imaging, and cellular and molecular analysis to understand the mechanisms driving response versus resistance.
Please reach out to us with any concerns or special requests.
909 Fannin St Suite 2000, Houston, TX 77010
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed